Cagrilintide vs Tirzepatide: What the Research Shows
Cagrilintide and Tirzepatide side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Cagrilintide if…
- you are weighing an investigational option (no FDA-approved product): in its phase 2 trial, mean weight reductions were greater with all cagrilintide doses than with placebo[8]
Consider Tirzepatide if…
- you want an FDA-approved product: Zepbound (tirzepatide) is labelled, with diet and activity, for chronic weight management in adults with obesity or with overweight plus a weight-related condition[16]
- you want large randomized weight-loss data (the SURMOUNT program): Mean weight change at week 72 was -15.0% (5 mg), -19.5% (10 mg) and -20.9% (15 mg) with tirzepatide versus -3.1% with placebo.[15]
- you are tested in sport and want to avoid a WADA-prohibited substance: Cagrilintide is prohibited by WADA at all times (check tirzepatide's own status separately)[4]
Spec comparison
Showing 8 of 12 fields where the two differ. Category, PCAC vote, Jul 2026, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.
| Field | Cagrilintide | Tirzepatide |
|---|---|---|
| Class | Amylin analog | GLP-1 / GIP dual agonist |
| Also called | cagri, cag | tirz, tirze, Mounjaro, Zepbound |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | Investigational (CagriSema component) | FDA approved (Mounjaro, Zepbound) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S0)Cagrilintide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change. | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Half-life | 159-195 h (with semaglutide 2.4 mg co-administered)subcutaneous · Lancet 2021, PMID 33894838 | approximately 5 dayssubcutaneous · FDA label (Mounjaro) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Clinical pharmacokinetics 2026, PMID 42228334 | Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163 |
| Human studies we summarised | 5 human (5 randomized or controlled) of 8 summarised | 24 human (22 randomized or controlled) of 30 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2.5 mg, 5 mg, 10 mg | 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg |
| Named in FDA warning letters, 2026 | Yes (31 Mar 2026) | Yes (24 Aug 2026; 31 Mar 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Cagrilintide and Tirzepatide together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 32 results, 2 Oct 2026).
What each trial measured
Tirzepatide's SURMOUNT-1 ran 72 weeks in adults with obesity and reported substantial, sustained reductions in body weight.[15]
In SURMOUNT-1, 85% of participants on tirzepatide 5 mg had a weight reduction of 5% or more.[15]
Cagrilintide's phase 2 trial was a dose-finding study that compared several weekly doses with liraglutide and with placebo.[8]
In the meta-analysis, cagrilintide monotherapy lowered blood pressure without meaningful HbA1c improvement.[14]
Practical differences
Tirzepatide's label gives a half-life of about 5 days and ties it to weekly dosing.[9]
In a phase 1b trial, cagrilintide's half-life was 159-195 h.[5]
Tirzepatide's SURMOUNT-1 abstract says the most common adverse events were gastrointestinal, mostly mild to moderate and occurring primarily during dose escalation.[15]
Common questions
Is cagrilintide better than tirzepatide?
No head-to-head trial is cited here. SURMOUNT-1 ran 72 weeks; the cagrilintide evidence cited is a dose-finding phase 2 trial plus a meta-analysis.[15]
Is cagrilintide available like Zepbound?
Drugs@FDA lists tirzepatide as Zepbound, a prescription product under application NDA217806. The cagrilintide FDA search on this site returned no match.[18]
Do both cause nausea?
Both studies report gastrointestinal adverse events as the most common, with nausea the leading symptom in cagrilintide's trial.[8]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
- 6Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026
- 7Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.Diabetes, obesity & metabolism · 2024PMID 39279639Accessed 2 Oct 2026
- 8Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet (London, England) · 2021PMID 34798060Accessed 2 Oct 2026
- 9These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 10Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 11Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
- 12Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 13PubMed search: (cagrilintide[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Annals of medicine and surgery (2012) · 2026PMID 42583410Accessed 2 Oct 2026
- 15Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
- 16ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 17Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2023PMID 37364590Accessed 11 Oct 2026
- 18Drugs@FDA (openFDA) search: active ingredient "tirzepatide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.